

CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:

Date: May 23, 2008 Name: Richard G. Lione, Reg. No. 19,795 Signature: /Richard G. Lione/

Our Case No. 5404/108

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Takahiro Ueda et al.	)	
	)	
International Serial No. PCT/JP2004/000117	)	Examiner: Sudhakar Katakam
	)	
U.S. Serial No.: 10/541,446	)	Group Art Unit: 1621
	)	
International Filing Date: January 9, 2004	)	Confirmation No. 6380
	)	
U.S. Filing Date: June 22, 2006	)	
	)	
Title: METHOD OF PURIFYING	)	
REDUCED COENZYME Q <sub>10</sub>	)	

**REQUEST FOR RECONSIDERATION**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The Office Action of February 4, 2008, contains a single rejection under 35 U.S.C. §103(a). Claims 1-19 are rejected under 35 U.S.C. §103(a) as being unpatentable over Merck & Co., Inc. (GB Patent No. 947,643) in view of "Kijima et al (US 4,061,660), Kijima et al (US 4,039,573) and Morita et al (US 4,163,664)."

The Examiner contends that the Merck & Co. reference teaches preparation and purification of reduced coenzyme Q<sub>10</sub> from the oxidized form of coenzyme Q<sub>10</sub> in ethanol,